Compare · ALB vs AMRS
ALB vs AMRS
Side-by-side comparison of Albemarle Corporation (ALB) and Amyris Inc. (AMRS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALB and AMRS operate in Major Chemicals (Industrials), so they compete in similar markets.
- ALB is the larger of the two at $11.59B, about 9.2x AMRS ($1.25B).
- ALB has hit the wire 5 times in the past 4 weeks while AMRS has been quiet.
- ALB has more recent analyst coverage (25 ratings vs 13 for AMRS).
- Company
- Albemarle Corporation
- Amyris Inc.
- Price
- -
- -
- Market cap
- $11.59B
- $1.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 13
Albemarle Corporation
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine Specialties, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets. It also provides cesium products for the chemical and pharmaceutical industries; zirconium, barium, and titanium products for pyrotechnical applications; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Bromine Specialties segment offers bromine and bromine-based fire safety solutions; specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals for use in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, water purification, beef and poultry processing, and other industrial applications; and other specialty chemicals, such as tertiary amines, biocides, disinfectants, and sanitizers. The Catalysts segment provides hydroprocessing, isomerization, and akylation catalysts; fluidized catalytic cracking catalysts and additives; and organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, crop protection, and custom chemistry services markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.
Amyris Inc.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Latest ALB
- Rocket Thrusters on a Road Car Arrive as EV Makers Split Into Winners and Laggards
- Albemarle upgraded by Mizuho
- Barclays initiated coverage on Albemarle with a new price target
- Director Wolff Alejandro Daniel was granted 45 shares, increasing direct ownership by 0.34% to 13,089 units (SEC Form 4)
- Albemarle Corporation to Release Third Quarter 2026 Earnings Results on Wednesday, November 4, 2026
- SEC Form SD filed by Albemarle Corporation
- Chief Commercial Officer Norris Eric was granted 10,867 shares, increasing direct ownership by 20% to 64,310 units (SEC Form 4)
- Chief Operations Officer Mummert Mark Richard was granted 6,086 shares, increasing direct ownership by 35% to 23,601 units (SEC Form 4)
- Chief People Officer Gagarinas Autumn M. was granted 5,217 shares, increasing direct ownership by 97% to 10,610 units (SEC Form 4)
- Chief Accounting Officer Hood Max was granted 1,476 shares (SEC Form 4)
Latest AMRS
- AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
- Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
- SEC Form S-8 POS filed by Amyris Inc.
- SEC Form S-8 POS filed by Amyris Inc.
- SEC Form S-8 POS filed by Amyris Inc.
- SEC Form S-8 POS filed by Amyris Inc.
- SEC Form POS AM filed by Amyris Inc.
- SEC Form POS AM filed by Amyris Inc.
- SEC Form S-8 POS filed by Amyris Inc.
- SEC Form S-8 POS filed by Amyris Inc.